Why the study?
Does warfarin prevent recurrent ischemic stroke or death compared to aspirin in patients requiring prevention of recurrent ischemic stroke?
Does warfarin prevent recurrent ischemic stroke or death compared to aspirin in patients requiring prevention of recurrent ischemic stroke?
Warfarin and aspirin demonstrate comparable efficacy and safety for the prevention of recurrent ischemic stroke over a two-year period.
Warfarin offers no advantage over aspirin for recurrent ischemic stroke prevention; confirms equivalence in this RCT and supports aspirin as first-line.
Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage. Consequently, we regard both warfarin and aspirin as reasonable therapeutic alternatives.
No takes yet. Share an insight, caveat, or question.
Mohr et al. (2001) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: